## AZN: AstraZeneca PLC - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.07 indicates fundamental undervaluation. Quality metrics strong (ROE 22%). Consistent execution (3/4 quarters beat estimates). Caution: declining volume (49% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($89.11)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Q4 EPS Estimates for AstraZeneca Boosted by Zacks Research**
- Source: MarketBeat | 20260102T130945 | Bullish | Relevance: 100%
- Zacks Research has increased its Q4 2027 EPS estimate for AstraZeneca to $1.60 per share, reflecting a consensus full-year earnings estimate of $4.51. The company holds a "Moderate Buy" rating from analysts with a target price of $95.75, following a recent quarter where it surpassed expectations with $1.19 EPS and 12% revenue growth. AstraZeneca (NASDAQ: AZN) is currently trading around $92 with a market cap of approximately $285.1 billion.

**2. My Personal CFO LLC Acquires Shares of 38,411 AstraZeneca PLC $AZN**
- Source: MarketBeat | 20260101T140926 | Bullish | Relevance: 100%
- My Personal CFO LLC has acquired 38,411 shares of AstraZeneca PLC valued at approximately $2.95 million, making it their 25th largest holding. Other institutional investors also significantly increased their stakes in AstraZeneca. The stock currently holds a "Moderate Buy" consensus rating from Wall Street analysts with an average target price of $95.75, following recent strong quarterly earnings results.

**3. 25,322 Shares in AstraZeneca PLC $AZN Purchased by Moody Lynn & Lieberson LLC**
- Source: MarketBeat | 20251231T120843 | Bullish | Relevance: 100%
- Moody Lynn & Lieberson LLC has acquired 25,322 shares of AstraZeneca PLC (NASDAQ:AZN) in the third quarter, valued at approximately $1.943 million, establishing a new position. AstraZeneca recently exceeded earnings expectations with EPS of $1.19 and revenue of $15.19 billion, reflecting 12% annual growth. The company maintains a "Moderate Buy" consensus rating from analysts with a price target of $95.75.

**4. Smith Salley Wealth Management Raises Stock Holdings in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251231T110843 | Bullish | Relevance: 100%
- Smith Salley Wealth Management significantly increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 770.4% in the third quarter of 2025, now holding 136,228 shares valued at approximately $10.45 million. This move follows AstraZeneca's strong Q3 performance, where it surpassed earnings and revenue estimates. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $95.75, close to its 12-month high.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.07 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $283.9B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.07 |
| Forward P/E | 17.8 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 0.9% (minimal 5-day change). Below STRENGTH zone by 3.1pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 54. Volume at 49% of 20MA suggests lack of conviction. OFD pattern: -MLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.91% (CS: 52) | Neutral |
| RSI_14 | 54.3 | Neutral |
| MACD Histogram | -0.13 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.033x | Above |
| vs SMA200 | 1.177x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $91.57
- **Stop Loss:** $89.11 (2.7% risk)
- **Target:** $96.49 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 585
- **Position Value:** $53,568.45
- **Portfolio %:** 53.57%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*